| Sun, Lingyun |
BEconneCTD-ILD, NCT06572384: A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease |
|
|
| Recruiting | 3 | 440 | Europe, Japan, US, RoW | Belimumab, BENLYSTA, GSK1550188, Placebo | GlaxoSmithKline | Lung Diseases, Interstitial | 10/28 | 12/28 | | |
NCT06716606: A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease |
|
|
| Recruiting | 3 | 225 | RoW | Belimumab | GlaxoSmithKline, ICON plc | Bronchial Diseases | 08/28 | 01/30 | | |
| Recruiting | 2/3 | 240 | Europe, Canada, Japan, US, RoW | EFG PH20 SC, PBO | argenx, argenx BV | Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome | 12/26 | 02/27 | | |
BLISSc-ILD, NCT05878717: A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease |
|
|
| Recruiting | 2/3 | 300 | Europe, Japan, US, RoW | Belimumab, BENLYSTA™, GSK1550188, LymphoStat-B™, BENLYSTATM, GSK1550188, LymphoStat-B™, Placebo | GlaxoSmithKline | Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic | 07/27 | 07/27 | | |
|
NCT04830644: A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome. |
|
|
| Recruiting | 2 | 144 | RoW | Iguratimod, Placebo | Jiangsu Simcere Pharmaceutical Co., Ltd. | Primary Sjögren Syndrome | 04/22 | 06/22 | | |
NCT06250062: A Clinical Study of JS005 in Patients With Ankylosing Spondylitis |
|
|
| Recruiting | 2 | 261 | RoW | Recombinant humanized IL-17A Monoclonal Antibody（JS005）, Placebo（JS005） | Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH | Ankylosing Spondylitis | 02/25 | 10/25 | | |
NCT06222671: A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA) |
|
|
| Not yet recruiting | 2 | 180 | RoW | 608, Placebo | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Axial Spondyloarthritis | 11/25 | 11/25 | | |
NCT05849727: A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis |
|
|
| Recruiting | 2 | 180 | RoW | TQH3821 tablets 200 mg, TQH3821 tablets matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Rheumatoid Arthritis | 06/24 | 12/24 | | |
| Completed | 2 | 456 | Europe, Japan, US, RoW | Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Systemic Lupus Erythematosus | 11/24 | 11/24 | | |
|
|
| Recruiting | 2 | 532 | Europe, Japan, US, RoW | M5049 low dose, Enpatoran, M5049 medium dose, M5049 high dose, Placebo, M5049 very high dose | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Merck Healthcare KGaA | Systemic Lupus Erythematosus | 04/25 | 04/25 | | |
NCT06058078: RY_SW01 Cell Injection Therapy in Active Lupus Nephritis |
|
|
| Recruiting | 2 | 60 | RoW | RY_SW01 cell injection, UC-MSC treatment, Basic treatment, Immunosuppressive drugs | Jiangsu Renocell Biotech Company, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Lupus Nephritis | 12/25 | 12/28 | | |
NCT06717815: Phase Ib/IIa Study for IPG11406 in Patients with Lupus Nephritis |
|
|
| Not yet recruiting | 1/2 | 36 | RoW | IPG11406 | Nanjing Immunophage Biotech Co., Ltd | Lupus Nephritis | 11/25 | 04/26 | | |
NCT04457856: A Study of TJ003234 in Rheumatoid Arthritis Patients |
|
|
| Recruiting | 1 | 63 | RoW | TJ003234 injection | I-Mab Biopharma Co. Ltd. | Rheumatoid Arthritis | 03/23 | 03/23 | | |
NCT06340490: A Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE) |
|
|
| Not yet recruiting | 1 | 24 | RoW | RJMty19 (CD19-CAR-DNT cells), Fludarabine, Cyclophosphamide | Guangdong Ruishun Biotech Co., Ltd, RenJi Hospital, Peking University People's Hospital, Changhai Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Systemic Lupus Erythematosus | 12/26 | 12/27 | | |
NCT06462144: IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy |
|
|
| Recruiting | 1 | 36 | RoW | IMPT-514 CART Cell Injection | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Systemic Lupus Erythematosus (SLE), ANCA Associated Vasculitis (AAV), Idiopathic Inflammatory Myopathy (IIM) | 05/25 | 10/26 | | |
| Wei, Wei |
NCT04263922: Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3 |
|
|
| Recruiting | 4 | 466 | RoW | Huaiqihuang granules, B12000050755, Valsartan capsule, H20030638 | The First Affiliated Hospital of Dalian Medical University, Huazhong University of Science and Technology, LinkDoc Technology (Beijing) Co. Ltd. | Renal Insufficiency, Chronic | 10/25 | 03/26 | | |
NCT05439629: Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | BAT5906 injection, Lucentis | Bio-Thera Solutions | Neovascular (Wet) Age-related Macular Degeneration | 04/24 | 06/25 | | |
BEconneCTD-ILD, NCT06572384: A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease |
|
|
| Recruiting | 3 | 440 | Europe, Japan, US, RoW | Belimumab, BENLYSTA, GSK1550188, Placebo | GlaxoSmithKline | Lung Diseases, Interstitial | 10/28 | 12/28 | | |
HAIC, NCT06041477: Concurrently vs Sequentially Combined With Targeted and Immunotherapy in Potentially Resectable HCC |
|
|
| Recruiting | 3 | 540 | RoW | Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU, Hepatic arterial infusion chemotherapy (HAIC), Concurrent Lenvatinib, Concurrent targeted therapy, Concurrent PD-1 antibody, Concurrent immunotherapy, Sequential Lenvatinib, Sequential targeted therapy, Sequential PD-1 antibody, Sequential immunotherapy | Sun Yat-sen University, The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine, Affiliated Hospital of Guangdong Medical University, First People's Hospital of Foshan | Hepatocellular Carcinoma, Chemotherapy Effect, Chemotherapeutic Toxicity | 07/27 | 07/30 | | |
IBS-D, NCT05687435: Changyanning Tablet for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome |
|
|
| Not yet recruiting | 2/3 | 240 | NA | Changyanning tablet, Changyanning tablet placebo | Mei Han | Diarrhea-Predominant Irritable Bowel Syndrome | 01/23 | 04/24 | | |
| Recruiting | 2/3 | 240 | Europe, Canada, Japan, US, RoW | EFG PH20 SC, PBO | argenx, argenx BV | Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome | 12/26 | 02/27 | | |
NCT05212051: Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active AS |
|
|
| Recruiting | 2 | 120 | RoW | JS005, Recombinant humanized anti-IL-17A monoclonal antibody injection, Placebo | Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH | Active Ankylosing Spondylitis | 11/22 | 01/23 | | |
NCT05242588: Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active Nr-axSpA |
|
|
| Recruiting | 2 | 120 | RoW | JS005, Recombinant humanized anti-IL-17A monoclonal antibody injection, Placebo | Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH | Non-radiographic Axial Spondyloarthritis | 04/23 | 06/23 | | |
NCT06301828: Endostar Combined With SBRT and Envafolimab in the Treatment of Advanced Gastrointestinal Tumors |
|
|
| Recruiting | 2 | 16 | RoW | Envafolimab Injection, KN035, Endostar, Recombinant Human Endostatin Injection | Nanjing First Hospital, Nanjing Medical University | Gastrointestinal Neoplasms | 06/25 | 02/26 | | |
NCT05688696: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus |
|
|
| Recruiting | 2 | 186 | RoW | Orelabrutinib (Low Dose), Orelabrutinib (High Dose), Orelabrutinib Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Systemic Lupus Erythematosus, SLE | 08/25 | 05/26 | | |
NCT05849727: A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis |
|
|
| Recruiting | 2 | 180 | RoW | TQH3821 tablets 200 mg, TQH3821 tablets matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Rheumatoid Arthritis | 06/24 | 12/24 | | |
| Completed | 2 | 456 | Europe, Japan, US, RoW | Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Systemic Lupus Erythematosus | 11/24 | 11/24 | | |
|
|
| Recruiting | 2 | 532 | Europe, Japan, US, RoW | M5049 low dose, Enpatoran, M5049 medium dose, M5049 high dose, Placebo, M5049 very high dose | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Merck Healthcare KGaA | Systemic Lupus Erythematosus | 04/25 | 04/25 | | |
NCT05998759: Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia |
|
|
| Recruiting | 2 | 296 | RoW | Telitacicept, recombinant human B lymphocyte stimulating factor receptor-Fc fusion protein, Recombinant Human B Lymphocyte(RC18), Tai'ai®, Placebo, Placebo control, control | Beijing Hospital, The First Affiliated Hospital of Anhui Medical University, The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial), Peking University People's Hospital, Peking University Third Hospital, First Affiliated Hospital, Sun Yat-Sen University, Guangdong Provincial People's Hospital, The First Affiliated Hospital of Zhengzhou University, Wuhan Union Hospital, China, Second Xiangya Hospital of Central South University, Xiangya Hospital of Central South University, The Affiliated Hospital of Inner Mongolia Medical University, First Hospital of China Medical University, Shandong Provincial Hospital, Changhai Hospital, RenJi Hospital, Shanxi Bethune Hospital, West China Hospital, Institute of Hematology & Blood Diseases Hospital, China, Tianjin First Central Hospital, Tianjin Medical University General Hospital, People's Hospital of Xinjiang Uygur Autonomous Region, The First People's Hospital of Yunnan | Connective Tissue Diseases, Thrombocytopenia | 12/25 | 12/25 | | |
| Completed | 1/2 | 60 | RoW | 2.5mg of BAT5906, 4.0mg of BAT5906 | Bio-Thera Solutions | Diabetic Macular Edema | 11/23 | 11/23 | | |
NCT05247203: Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus |
|
|
| Completed | 1 | 92 | RoW | Telitacicept, RC18, standard therapy | RemeGen Co., Ltd. | Systemic Lupus Erythematosus | 10/23 | 11/23 | | |
| Recruiting | N/A | 10254 | RoW | | Limeng Chen | Chronic Kidney Diseases, Chronic Kidney Disease-Mineral and Bone Disorder | 12/24 | 12/24 | | |
NCT06297889: Effect of Core Strength Training on the Physical Fitness and Skills of Youth Field Hockey Players in China |
|
|
| Recruiting | N/A | 48 | RoW | core strength training 1-6weeks, core strength training 7-12weeks | Universiti Putra Malaysia | Player | 06/24 | 06/24 | | |
NCT06662071: A Research Protocol for Evaluating the Efficacy of Perfused Chemotherapeutic Agents for Bladder Cancer Based on Organoid Technology |
|
|
| Recruiting | N/A | 293 | RoW | Organoid culture | Qilu Hospital of Shandong University, The Second Hospital of Shandong University, The First Affiliated Hospital of Shandong First Medical University, Shandong Provincial Hospital, The Third Shandong Provincial Hospital, Taian City Central Hospital, Weifang People's Hospital, Binzhou Medical University, The Affiliated Hospital of Qingdao University, Jining First People's Hospital, Liaocheng People's Hospital, Linyi People's Hospital, Yantai Yuhuangding Hospital, Zibo Central Hospital, Dezhou People's Hospital, The Affiliated Hospital of Jining Medical University and Zaozhuang City, Qilu Hospital of Shandong University (Qingdao) | Bladder Cancer | 09/28 | 09/28 | | |
| Recruiting | N/A | 33 | RoW | Growth Inhibitor | Second Affiliated Hospital, School of Medicine, Zhejiang University | Acute Esophageal Variceal Hemorrhage | 05/26 | 08/26 | | |
IBS, NCT06013410: Pathophysiological Effects of Persistently Colonized Microbiome on Irritable Bowel Syndrome |
|
|
| Recruiting | N/A | 30 | RoW | colonoscopy | Second Affiliated Hospital, School of Medicine, Zhejiang University, Jinhua Hospital | Irritable Bowel Syndrome | 05/26 | 05/26 | | |
| Recruiting | N/A | 2000 | RoW | | Peking Union Medical College Hospital | Anti Phospholipid Syndrome | 12/26 | 12/26 | | |
| Lu, Liangjing |
| Completed | 2 | 456 | Europe, Japan, US, RoW | Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Systemic Lupus Erythematosus | 11/24 | 11/24 | | |
|
|
| Recruiting | 2 | 532 | Europe, Japan, US, RoW | M5049 low dose, Enpatoran, M5049 medium dose, M5049 high dose, Placebo, M5049 very high dose | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Merck Healthcare KGaA | Systemic Lupus Erythematosus | 04/25 | 04/25 | | |
NCT06414135: Relmacabtagene Autoleucel for the Treatment of Systemic Sclerosis |
|
|
| Recruiting | 1 | 6 | RoW | Relma-cel | Liangjing Lu, Shanghai Ming Ju Biotechnology Co., Ltd. | Systemic Sclerosis | 05/25 | 04/27 | | |
NCT06567080: JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases |
|
|
| Not yet recruiting | 1 | 15 | RoW | JWCAR201 | RenJi Hospital, Shanghai Ming Ju Biotechnology Co., Ltd. | B-cell Tumors, Autoimmune Diseases, Lupus Erythematosus, Systemic, Large B-cell Lymphoma | 09/25 | 03/27 | | |
| Recruiting | N/A | 400 | RoW | biomarkers detection in different groups | RenJi Hospital | Lupus Nephritis | 08/21 | 08/21 | | |
NCT03671174: Immunosuppressant Regimens for Living Fetuses Study |
|
|
| Recruiting | N/A | 420 | RoW | Prednisone, Hydroxychloroquine, Aspirin, low molecular weight heparin, Enoxaparin, Dalteparin, Nadroparin | RenJi Hospital, The First Affiliated Hospital of Anhui Medical University, China-Japan Union Hospital, Jilin University, Wuxi No. 2 People's Hospital, The First Affiliated Hospital with Nanjing Medical University, Xiangya Hospital of Central South University | Undifferentiated Connective Tissue Disease, Recurrent Pregnancy Loss | 09/21 | 02/23 | | |
| Not yet recruiting | N/A | 100 | RoW | Certolizumab Pegol 200 MG/ML [Cimzia], Hydroxychloroquine, Prednisone | RenJi Hospital | Rheumatoid Arthritis, Pregnancy Related | 12/22 | 12/23 | | |
| Nowak, Agata |
| Recruiting | 2 | 532 | Europe, Japan, US, RoW | M5049 low dose, Enpatoran, M5049 medium dose, M5049 high dose, Placebo, M5049 very high dose | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Merck Healthcare KGaA | Systemic Lupus Erythematosus | 04/25 | 04/25 | | |
| Wytyk-Nowak, Agata |
RESOLUTION-1, NCT05516758: A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis |
|
|
| Completed | 2 | 491 | Europe, Canada, Japan, US, RoW | Peresolimab, Placebo | Eli Lilly and Company | Rheumatoid Arthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases, Connective Tissue Diseases, Autoimmune Diseases, Immune System Diseases | 11/23 | 01/25 | | |
NCT05123586: A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus |
|
|
| Terminated | 2 | 85 | Europe, US, RoW | LY3361237, Placebo | Eli Lilly and Company | Systemic Lupus Erythematosus | 12/23 | 12/23 | | |
| Completed | 2 | 456 | Europe, Japan, US, RoW | Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Systemic Lupus Erythematosus | 11/24 | 11/24 | | |
|
|
| Recruiting | 2 | 532 | Europe, Japan, US, RoW | M5049 low dose, Enpatoran, M5049 medium dose, M5049 high dose, Placebo, M5049 very high dose | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Merck Healthcare KGaA | Systemic Lupus Erythematosus | 04/25 | 04/25 | | |
